TRXC - TransEnterix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
6.87
+0.40 (+6.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.47
Open6.60
Bid0.00 x 800
Ask0.00 x 2200
Day's Range6.47 - 6.87
52 Week Range1.20 - 6.87
Volume8,856,956
Avg. Volume7,075,590
Market Cap1.436B
Beta2.20
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • TransEnterix's MST Medical Buyout to Boost Senhance Platform
    Zacks22 hours ago

    TransEnterix's MST Medical Buyout to Boost Senhance Platform

    TransEnterix (TRXC) acquires Israel-based MST Medical, which will boost surgeons' effectiveness and make procedures quick and error-free.

  • ACCESSWIRE23 hours ago

    Today's Research Reports on Trending Tickers: TransEnterix and Neovasc

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / U.S. markets were mixed on Friday, with the Dow Jones managing to close at an all-time high despite a plunge in technology and internet stocks. The Dow Jones Industrial Average gained 0.32 percent to close at 26,743.50, while the S&P 500 Index declined 0.04 percent to close at 2,929.67.

  • Business Wire2 days ago

    TransEnterix Acquires Assets, Intellectual Property and Retains R&D Team from MST Medical Surgery Technologies

    TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced that it has acquired substantially all of the assets of MST Medical Surgery Technologies Ltd. (“MST”), an Israel medical technology company, in a cash and stock transaction with a total consideration, further described below. MST is a leader in the field of surgical technology, having developed a software-based image analytics platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics.

  • How Financially Strong Is TransEnterix Inc (NYSEMKT:TRXC)?
    Simply Wall St.4 days ago

    How Financially Strong Is TransEnterix Inc (NYSEMKT:TRXC)?

    Investors are always looking for growth in small-cap stocks like TransEnterix Inc (NYSEMKT:TRXC), with a market cap of US$1.36b. However, an important fact which most ignore is: how financially healthyRead More...

  • Business Wire5 days ago

    TransEnterix to Participate in Two Upcoming Healthcare Conferences

    TransEnterix, Inc. announced today that TransEnterix will participate in two upcoming healthcare conferences:

  • CNBC12 days ago

    Cramer's lightning round: I'm not the call on how to play Roku

    Jim Cramer rattles off his take on callers' favorite stocks, including a streaming play that he's gotten wrong in the past.

  • Motley Fool14 days ago

    How Intuitive Surgical, Inc. Shares Went Up 10% Last Month

    The robotic surgery specialist posted another big month on nothing more substantial than a single, tight-lipped analyst action.

  • Business Wire19 days ago

    TransEnterix Announces FDA 510(k) Submission for Senhance Ultrasonic Instrument System

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company filed a FDA 510(k) submission for its Senhance Ultrasonic Instrument System. Advanced energy devices, including ultrasonic devices, represent some of the most versatile and critical tools for surgeons in minimally invasive surgery. “Advanced energy devices are an important tool within laparoscopic surgery because of their applicability within a wide range of procedures,” said Todd M. Pope, TransEnterix CEO.

  • Business Wire21 days ago

    TransEnterix, Inc. Appoints Eric Smith as Chief Commercial Officer

    TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018. In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence. “We are very excited to have Eric join the TransEnterix team.

  • TransEnterix Stock Saw 18% Growth in Week Ended August 24
    Market Realist29 days ago

    TransEnterix Stock Saw 18% Growth in Week Ended August 24

    On August 24, TransEnterix (TRXC) stock closed at $5.37, which represents a ~6.13% growth from its prior day’s close of $5.06. On August 24, TransEnterix closed at $5.37, which is ~12% below its 52-week high of $6.04 on June 27. TransEnterix, a medical device company, is focused on the development of minimally invasive surgical devices with the digitalization of the interface between the surgeon and the patient.

  • TransEnterix Expected to Report Solid Rise in Revenues in 2018
    Market Realistlast month

    TransEnterix Expected to Report Solid Rise in Revenues in 2018

    TransEnterix (TRXC) expects to sell three Senhance systems in Q3 2018. While the company expects lower capital sales in the third quarter, it expects sales to be stronger in Q4 2018. Wall Street analysts have projected TransEnterix’s fiscal 2018 revenues to be around $24.7 million, which would be a YoY rise of approximately 248%.

  • What Analysts Recommend for TransEnterix and Peers in August 2018
    Market Realistlast month

    What Analysts Recommend for TransEnterix and Peers in August 2018

    In Q2 2018, TransEnterix (TRXC) sold four Senhance surgical robots. Senhance is approved in the US for multiple digital laparoscopic procedures such as an inguinal hernia, colorectal surgery, cholecystectomy surgery, and gynecologic surgery. TransEnterix aims to expand the penetration of surgical robotics globally, which currently stands under 10%.

  • Business Wirelast month

    TransEnterix to Present at the 13th Annual Wells Fargo Securities Healthcare Conference

    TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference at The Westin Copley Place in Boston, Massachusetts.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of TRXC earnings conference call or presentation 7-Aug-18 12:30pm GMT

    Q2 2018 Transenterix Inc Earnings Call

  • Inside The List: Breakdown of size, location of NC's publicly traded companies
    American City Business Journalslast month

    Inside The List: Breakdown of size, location of NC's publicly traded companies

    In its latest look at the financials of these publicly traded companies, Triangle Business Journal dove deeper into the data to see how these companies fall in the various regions of the state and how those areas stack up as of July 31, 2018 – and how these companies compare to last year.

  • Why TransEnterix Stock Rocketed Higher in July
    Motley Foollast month

    Why TransEnterix Stock Rocketed Higher in July

    Shares of this tiny robotic-surgery company benefited from a positive corporate update last month.

  • Some highs, lows as RTP biotech companies report earnings
    American City Business Journals2 months ago

    Some highs, lows as RTP biotech companies report earnings

    Earnings season is in full swing, and companies are busy reporting their performance for the second quarter of the fiscal year.   The same is true for Research Triangle Park’s biotech companies, BioDelivery Sciences (Nasdaq: BDSI), TransEnterix (Amex: TRXC) and Dova Pharmaceuticals (Nasdaq: DOVA) all announced their financial results during after-market hours in recent days.

  • Why TransEnterix Shares Dropped 11.7% Today
    Motley Fool2 months ago

    Why TransEnterix Shares Dropped 11.7% Today

    An increase in robotic surgery system sales failed to offset concerns over the company's net loss.

  • An Overview of TransEnterix’s Q2 2018 Results
    Market Realist2 months ago

    An Overview of TransEnterix’s Q2 2018 Results

    TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017. 

  • TransEnterix sees revenue climb on surgical robot sales
    American City Business Journals2 months ago

    TransEnterix sees revenue climb on surgical robot sales

    TransEnterix (NYSE: TRXC) is seeing its revenue climb on more sales following its initial U.S. Food and Drug Administration clearance late last year, although the company is still showing losses overall. On Tuesday, the Research Triangle Park-based surgical robot maker reported revenue of $6.4 million in the second quarter of 2018, compared to revenue of just $1.6 million in the second quarter of last year. TransEnterix reported a net loss of $34.2 million, or $0.17 per share, for the second quarter of 2018, compared to a net loss of $14.7 million, or $0.11 per share, for the second quarter of last year.

  • TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates

    TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and 3.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    TransEnterix: 2Q Earnings Snapshot

    The Morrisville, North Carolina-based company said it had a loss of 17 cents per share. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of surgical robots ...

  • Business Wire2 months ago

    TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2018

    TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter 2018.

  • ACCESSWIRE2 months ago

    TransEnterix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / TransEnterix, Inc. (NYSE American: TRXC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • One trader's big call on Target
    CNBC Videoslast month

    One trader's big call on Target

    Steve Weiss: investors need to hit this target.